Rectal Artesunate Suppository
Please refer to the full prescribing information and/or patient information supplied by the relevant marketing authorization holder for your country, as well as local policies and treatment guidelines as they may vary from country to country.
Manufacturers listed on this page meet internationally agreed quality standards. For more information on quality assured medicines, refer to the WHO Prequalification Programme and the Global Fund's strategy on quality assurance of medicines.
| Manufacturer | Registration status | Formulation |
|---|---|---|
| Cipla Limited | WHO prequalified |
100 mg suppository (2 per pack) |
| Strides Shasun | Quality assured by Global Fund’s Expert Review Panel (ERP) |
100mg formulation (2 per pack) |
The Artesunate Rectal Capsule (ARC) or artesunate suppository is strongly recommended by the WHO for pre-referral intervention of children between six months and six years when they present with danger signs, when a complete course of severe malaria treatment is not available and when the patient cannot take oral medication. After the suppository is administered, children should be immediately referred to an appropriate facility for treatment, ideally for intravenous treatment with injectable artesunate followed by a full treatment course with an ACT.
Dosing table for artesunate rectal capsules
| Category | Dosage |
|---|---|
| Children between 6 months and 6 years | 10 mg/kg bodyweight |
WHO does not recommend artesunate rectal capsules use in older children and adults
